

SUPPLEMENTAL MATERIAL

von Moltke et al., <https://doi.org/10.1084/jem.20161274>




Figure S1. **LT biosynthesis and antibodies and primers used in this study.** (A) Schematic of LT biosynthesis pathway. Mice deficient for genes listed in bold were used in this study. Double lines indicate binding. (B) Flow cytometry antibodies used in this study. (C) Quantitative RT-PCR (qRT-PCR) primers used in this study.




Figure S2. **Gating strategies for cell sorting.** (A) Gating strategy for sorting ILC2 and CD4 cells from the lungs of wild-type mice for quantitative RT-PCR. (B) Gating strategy for sorting eosinophils from blood of wild-type mice for quantitative RT-PCR. (C) Gating strategy for sorting ILC2s from *Il13^{Smart/Smart}* mice. (D) Gating strategy for sorting ILC2s from *Arg1^{Yarg/Yarg}·Il13^{Smart/Smart}* mice with the addition of anti-IL-33R(ST2) antibody. (E) Gating strategy for sorting ILC2s from *Arg1^{Yarg/Yarg}·Il13^{Smart/Smart}* mice without anti-IL-33R(ST2) antibody. Data are representative of at least three independent experiments. mac, macrophage; SSC, side scatter.




Figure S3. **Flow cytometry gating strategies.** (A) Representative Smart13 reporter gating for ILC2s sorted from the indicated mice and stimulated 6 h in vitro as indicated. (B) Gating strategy for analysis of lung eosinophils, ILC2s, and in vivo Smart13 reporter expression. Data are representative of at least three independent experiments. SSC, side scatter.